Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
45.99
-0.09 (-0.20%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Mirum Pharmaceuticals stock have an average target of 58.55, with a low estimate of 38 and a high estimate of 74. The average target predicts an increase of 27.31% from the current stock price of 45.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $66 → $72 | Strong Buy | Maintains | $66 → $72 | +56.56% | Feb 28, 2025 |
| Baird | Baird | Buy Maintains $50 → $55 | Buy | Maintains | $50 → $55 | +19.59% | Feb 27, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $74 | Buy | Reiterates | $74 | +60.90% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +43.51% | Nov 13, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $65 → $68 | Strong Buy | Maintains | $65 → $68 | +47.86% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
428.69M
from 336.89M
Increased by 27.25%
Revenue Next Year
522.19M
from 428.69M
Increased by 21.81%
EPS This Year
-0.94
from -1.85
EPS Next Year
-0.32
from -0.94
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 461.9M | 596.3M | 782.8M | ||
| Avg | 428.7M | 522.2M | 652.7M | ||
| Low | 384.2M | 449.8M | 562.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.1% | 39.1% | 49.9% | ||
| Avg | 27.3% | 21.8% | 25.0% | ||
| Low | 14.0% | 4.9% | 7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.01 | 0.32 | 1.46 | ||
| Avg | -0.94 | -0.32 | 0.78 | ||
| Low | -1.47 | -1.59 | -0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.